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Over the past four decades, two issues have driven the health care ﬁnanc-
ing debate: costs and coverage. If you dug a little deeper, I think you 
would ﬁnd that the real driver of the debate has been the cost issue rather 
than the coverage issue, and discussion of the cost issue has focused more 
often than not on the federal budgetary impact. It has not been an abstract 
debate about 13 percent of GDP versus 15 percent of GDP. Rather, it has 
been about the impact of health care spending on the federal budget, and 
the consequence of that focus has been a skewing of attention towards 
Medicare, with Medicaid getting beat up the most, and a kind of tip-toe-
ing around the private sector.
Coverage, which I certainly ﬁnd to be the more morally compelling 
issue, has been debated broadly and unsuccessfully about once each 
decade—in 1974, 1980, and 1994—and I will come back to that in con-
cluding, after saying a bit about costs.
You have been hearing about costs all morning. It is my belief also 
that costs will go up, that the increasing costs of all the blessings of mod-
ern medicine—drugs, technologies, devices, pharmaceuticals—will quite 
likely more than offset any of the vaunted potential savings from admin-
istration, information technology, and evidence-based medicine. So, I 
think we are going to face continued increases in costs.
This puts more pressure on all of us in this sector to implement every-
thing that might impact costs, because the pressure for us to demonstrate 
value is going to increase exponentially as costs climb beyond 15 percent 
of GDP. I do not necessarily take this as a message that says we should 
quit. Rather, I take this as a message that says we are going to have to do 
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everything we can and then some. Let me start by talking about what we 
can do, and then I will move to the “then some.”
There are real steps that we can take to limit cost increases and enhance 
value. I will set out three of them here. The ﬁrst relates to some signiﬁcant 
commentary that you have just heard about electronic medical records. 
I have become a believer that this is real. Many people think this is only 
about cutting down paperwork in medicine. It is about far more than 
cutting down paperwork, however. It is really about being able to drive 
medicine towards evidence-based practice through the use of various 
prompts, rules, algorithms, and things of that sort. So, there is tremen-
dous potential here.
It is going to be a huge undertaking. The Bush administration budget 
request was for $100 million, whereas in one large system in one city 
alone, we are spending $50 million on this issue. Sizing the Bush budget 
request against what we are spending may not be a fair shot, because 
it has been made clear by the administration—at least as I understand 
it—that at present they do not view it as their role to be the primary 
ﬁnancier of all this. However, if they are not the ﬁnancier, then either 
private payers or the hospitals are going to have to pay, and the medical 
providers are going to have to wring the rest out of what they do. Some-
body is going to have to pay this bill. It is a signiﬁcant bill, as the spend-
ing contrast mentioned above shows. So, it is very signiﬁcant, although 
I think that moving to electronic medical records has huge potential for 
savings.
Pay for performance verges on being a cliché, so I have to be very 
careful in this area. But it has the potential to cut a middle path between 
fee-for-service, which arguably emphasizes that there is overprovision of 
services, and capitation, which arguably emphasizes that there is a poten-
tial underdelivery of services. Having said that I recognize that pay for 
performance can be a cliché, I believe it is a reality in Boston. Our con-
tracts with all three of the major payers—Blue Cross, Harvard Pilgrim, 
and Tufts—are based on pay-for-performance standards in terms of days 
of hospitalization, drug trend, and radiology trend. So, I believe that it 
can be made real.
Finally, another issue that can be an old chestnut is disease manage-
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the past decade by really meaning not paying bills, particularly in the 
mental health area. That is not what I mean by disease management. I 
am driven more by the statistics that many of you have heard: 10 percent 
of people account for 70 percent of costs, and 1 percent account for 30 
percent of costs. It just seems to be tautological that you should be able 
to gain in both quality and efﬁciency by putting more emphasis and focus 
on the management of the care of these very, very sick patients.
Again, we have examples in Boston of real progress with several con-
gestive heart failure disease management programs that have cut down 
on hospital readmissions. We are working with the state on seeing 
whether we can put in place some special support services for our 1,000 
most expensive Medicaid patients. So, I think there is great promise here. 
These are among the things that we can, should, and must do as we go 
forward into the next decade.
However, even having done all that, I think that costs are going to 
remain a problem, and that there are two ultimate public policy issues 
for the out years. Frankly, if you are a senator or a congressman, I think 
that maybe you can dodge this bullet for another ﬁve or 10 years. I do 
not think that you can dodge it for 15 or 20, however. The ﬁrst question 
is: Is 15 percent of GDP too much to spend for health care? Certainly, 
the common wisdom has been that the easy answer is “yes,” with facile 
comparisons to other international systems and commonly held assump-
tions on waste and abuse. 
More recently, there are some developing arguments that it is not nec-
essarily too much, that higher health expenditures yield value compared 
with the other things we are buying in GDP, and that obviously we have 
this ever-aging population and the march of biomedical science. So, in 
fact, if the public as consumers want to consume more than 15 percent of 
GDP in the form of improved health, we may not have the easy answer 
we thought we had to this question. However, if health care spending 
goes up, there are clear tax consequences, as was explained earlier by 
Henry Aaron and other speakers.
The second and the more pressing public policy question in this out-
year period is: If health care spending as a percent of GDP is too high, 
what can we do about it? And here, so far as I know after 35 years in this 
business, there simply are no easy answers. The default answer is to let 
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health care spending rise with GDP. My guess is that we will continue on 
the path of the default answer because the other answer is so problematic 
that people are not going to want to embrace it quickly. The other answer, 
so far as I know, is rationing. (I have not heard the word explicitly used 
this morning, but we might as well bring it out of the closet.) And, so far 
as I know—the economists in the audience know more about this than 
I do—there are two ways to ration. One is by what I call “real market 
forces,” and I do not think we are talking about $20 co-payments here. 
We are talking about real market pain, which will lead to great disparities 
between the care of the rich and the care received by the middle class and 
the poor. Even though this sounds like the politically easy answer, as it 
plays out it may not appear nearly so politically easy. We are much more 
ready to accept a society that allows some people to have the resources 
to stay in a Four Seasons hotel while others stay in a Sheraton, and still 
others stay in a Motel 6 or no hotel at all, than to accept similar dis-
parities in health care. We have tough free-market rhetoric, but when the 
consequences are shown on TV, even the most rock-ribbed conservative 
politician tries to get a liver for Baby Jessica or famously tries to keep 
Terry Schiavo alive on a feeding tube. So, I think this is going to be a lot 
tougher than people realize. 
Of course, the other path to rationing is the approach taken by almost 
the entire rest of the world, and that path is rationing by government 
and private payer limits. But, again, people are grownups and know that 
that is not an easy answer, and is an approach that often leads to arbi-
trary consequences—queuing and other things that we have all seen in 
the much-heralded bashing of the English and Canadian systems. 
So, I ﬁnd no easy answers here in the out years. I think this means that 
we have to keep doing everything we can do. The default answer will be 
that costs will grow, but at some point the tax consequences will be so 
severe that people will start edging up to one or the other version of the 
alternative or some combination.
At this point, I want to move towards some comments on the coverage 
issue—the obviously linked, twin issue. I will make three assertions here 
and then make a few comments about each.
The ﬁrst assertion is that health insurance coverage is not only about 
money. It is really about health. Second—and Judy Feder made exactly 
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watching this is that expansion of coverage should not wait until we 
solve all of these other cost issues. We are holding the uninsured hos-
tage to our inability as a society to deal with these issues. We ought 
to put everybody on a level playing ﬁeld and then deal with the cost 
issues. Also, over four decades, health care issues have always been 
trumped by the politics and economics of the issues. Speciﬁcally, the anti-
tax movement, which I believe has been the strongest political force of 
the past 30 years, has trumped the issue of providing broader health   
coverage.
I said this is about health, not just dollars. I served on the National 
Academies’ Institute of Medicine (IOM) Commission in 2003, which 
looked at this. That committee’s report on the uninsured found that, 
compared with the insured, the uninsured were less likely to have seen 
a physician in past years, more likely to go without care, less likely to 
receive preventive care, and twice as likely to be hospitalized for avoid-
able complications of diabetes or high blood pressure. The IOM report 
led up to the ﬁnding that there were about 18,000 premature deaths a 
year among people under 65 years of age as a result of being uninsured. 
That ﬁnding leads me to the conclusion that everyone who is interested 
in the “culture of life” should be ﬁghting for, rather than opposing, uni-
versal coverage. We need a switch in the political framing.
However, the coverage debate is also about dollars, and, again, this 
same IOM Commission looked carefully at this issue. I will speciﬁcally 
cite just a few things. The estimated cost of services needed but not 
received by the uninsured is $35 billion to $70 billion. This amounts to 
3 to 5 percent of health spending, or about half of each year’s annual 
increase. The estimated cost of legislation would be a bit higher—$70 bil-
lion to $100 billion annually—because such legislation usually has addi-
tional aims, like subsidizing employers or giving states ﬁscal relief. 
The estimated return to society from improved health would be some-
where in the range of $65 billion to $130 billion. At this point, you may 
be asking: If we could do this for the price of one year’s increase and if the 
cost would be offset by the savings, why don’t we do it? Well, we don’t do 
it ﬁrst and predominantly because—as was mentioned this morning—the 
returns don’t go to those who pay. Health care ﬁnancing involves a huge 
income transfer from healthy people to sick people, from wealthy people 
to poor people, and from young people to old people.
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We are also blocked because we hope that coverage expansion will 
be paid for by efﬁciency savings, but, as I indicated, I do not think that 
they are likely to occur—at least not in sufﬁcient magnitude. And if they 
do, they are not likely to be captured for coverage expansion. Nobody is 
going to give those dollars to me to use for universal coverage. They are 
going to go back into people’s pockets, and people are not clamoring to 
pay for the health care of others, as was noted this morning.
In the end, it does all come down to taxes. I think the triumphant 
conservative political movement of the past 30 years has had one major 
value to which they have stuck tenaciously, and that is an ever-lower 
level of taxation. We have seen some success in that on their part. Federal 
taxes in the 1990s, one of the most productive economic eras we have 
ever seen, averaged 18.5 percent of GDP. They are 16.3 percent of GDP 
now. That difference amounts to $200 billion. That is twice the amount 
of money that would be needed to cover the uninsured. There is a fun-
damental political choice in front of us: Do we want a society that can 
boast of and have the consequences of the lowest taxes in 40 years, or 
do we want to see expanded health insurance coverage, which supports 
people’s health, social justice, and the culture of life that we hear so much 
about?